期刊
CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 106, 期 1, 页码 94-102出版社
WILEY
DOI: 10.1002/cpt.1409
关键词
-
资金
- National Institutes of Health (NIH) [R24GM115264, U24HG010135-01, R24GM61374, R24GM123930]
- [R01HD058556]
- [U54HD090258]
Atomoxetine is a nonstimulant medication used to treat attention-deficit/hyperactivity disorder (ADHD). Cytochrome P450 (CYP)2D6 polymorphisms influence the metabolism of atomoxetine thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for atomoxetine based on CYP2D6 genotype (updates at ).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据